Equasens (LTS:0R9T) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0R9T Equasens LTS:0R9T
81 GF Score
Price €33.55
GF Value €57.04
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Equasens Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Equasens Valuation Rank Related Terms

LTS:0R9T
81GF Score
Equasens LTS:0R9T
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Equasens (LTS:0R9T) Overvalued in 2026?

Based on GuruFocus' analysis, Equasens stock appears to be undervalued. The current stock price of €33.55 is trading 41.2% below its estimated GF Value™ of €57.04. GuruFocus considers Equasens to be Significantly Undervalued.

Key valuation signals for LTS:0R9T:

  • Valuation Rank:
  • GF Value™: €57.04 vs. price of €33.55 (41.2% below fair value)
  • GF Score™: 81/100 with 3 warning signs

No single metric tells the full story. See the LTS:0R9T stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Equasens Business Description

Address 5 Allee de Saint-Cloud, Technopole de Nancy Brabois, Villers-les-Nancy, FRA, 54600
Equasens is engaged in the European healthcare sector, providing software solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, Hospital-at-Home structures, retirement homes, health centers) and patients in both primary and secondary care sectors. The various activities that the company is involved in include: pharmacy software publishing and integration, publishing of IT solutions for health and medical/social establishments, and development of solutions and infrastructures for e-Health. With operations in France (its key revenue-generating market), Italy, Belgium, Germany, Ireland, and the United Kingdom, it is developing the healthcare platform and an ecosystem in France and Europe, benefiting people by making its technology services available.
81GF Score

Get the complete analysis for LTS:0R9T

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€33.55
Price
€57.04
GF Value